文献速递颈动脉与弓上血管

颈动脉疾病治疗患者结局的地区差异:血管质量倡议研究

Regional variation in patient outcomes in carotid artery disease treatment in the Vascular Quality Initiative.
PubMed 文献 · J Vasc Surg · 2018-03-20

基于血管质量倡议(VQI)2009至2016年78467例颈动脉血运重建病例,评估颈动脉内膜剥脱术(CEA)与颈动脉支架置入术(CAS)围术期结局的地区差异。CAS组无症状及症状患者卒中/死亡存在地区差异,部分地区未达美国心脏协会(AHA)指南标准;CEA组各地区的卒中/死亡均在AHA标准内,但队列内存在显著地区差异。

要点

  • CAS无症状患者卒中/死亡0%-5.8%(P = .03),部分地区的发生率超出AHA指南3%的标准
  • CEA无症状患者卒中/死亡0.9%-3.1%,症状患者1.3%-4.9%,均在AHA标准内但地区差异显著
  • CEA后颅神经损伤、重返手术室及出院抗血小板和他汀使用均存在显著地区差异

核心结论

  • 颈动脉血运重建结局在VQI各地区的存在不合理的地区差异。
  • 在现有质量指标所覆盖的若干结局(如住院时长和出院用药)中观察到显著差异。
  • CAS后部分地区未达AHA关于卒中和死亡的指南标准。
  • 作者认为质量改进项目应针对提高对现行指南的依从性以促进最佳实践。

研究设计与样本

  • 回顾性分析血管质量倡议(VQI)2009至2016年所有接受CEA或CAS的患者,按症状状态分层。
  • 共识别78467例颈动脉干预,其中85%为CEA,CEA中69%为无症状;CAS中39%为无症状。
  • 采用χ2分析、Fisher精确检验和t检验评估围术期结局的地区差异。

主要发现

  • CAS无症状组卒中/死亡0%-5.8%(P = .03),症状组2.4%-8.1%(P = .1),风险调整后仍有地区未达AHA标准。
  • CEA无症状组卒中/死亡0.9%-3.1%(P < .01),症状组1.3%-4.9%(P < .01),均在AHA标准内。
  • 30天死亡:症状患者CEA 0%-1.8%(P < .01)、CAS 0%-4.6%(P = .01);无症状患者CEA 0%-1.3%(P = .2)、CAS 0%-2.4%(P = .2)。
  • CEA后颅神经损伤无症状0.9%-4.9%、症状1.5%-7.7%(均P < .01);重返手术室无症状0.9%-3.4%(P < .01)、症状0.6%-3.4%(P = .02)。
  • CAS后穿刺部位并发症无症状2.3%-18.2%、症状1.4%-16.9%(均P < .01);出院双联抗血小板无症状79%-94%、症状83%-93%(均P < .01)。

关键数值与推荐

  • AHA指南标准:无症状患者卒中/死亡3%,症状患者6%。
  • CEA无症状组出院抗血小板和他汀75%-87%(P < .01),症状组78%-91%(P < .01)。
  • 住院期间卒中、术后心肌梗死、住院时长>2天及静脉降压药使用均存在显著地区差异(原文未报告各数值)。

临床怎么用

  • 作者认为质量改进项目应针对提高对现行指南的依从性以促进最佳实践。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Quality metrics were developed to improve outcomes after carotid artery revascularization; however, few studies have evaluated regional differences in perioperative outcomes. This study aimed to evaluate regional variation in mortality and perioperative outcomes after carotid endarterectomy (CEA) and carotid artery stenting (CAS). METHODS: We identified all patients who underwent CEA or CAS from 2009 to 2016 in the Vascular Quality Initiative. Patients were analyzed on the basis of their symptom status. We assessed variation in perioperative outcomes using χ2 analysis, Fisher exact test, and t-test, where appropriate. RESULTS: A total of 78,467 carotid interventions were identified; 85% were CEAs, with 69% of those asymptomatic. Within CAS, 39% were asymptomatic. Perioperative stroke/death varied across regions within both CAS groups (asymptomatic, 0%-5.8% [P = .03]; symptomatic, 2.4%-8.1% [P = .1]), and several regions did not meet the American Heart Association (AHA) guidelines of 3% for asymptomatic patients and 6% for symptomatic patients, which persisted after risk adjustment. For CEA, the stroke/death rates fell within the standards set by the AHA guidelines in all regions for both the unadjusted and risk-adjusted models; however, there was significant regional variation in the cohorts (asymptomatic, 0.9%-3.1% [P < .01]; symptomatic, 1.3%-4.9% [P < .01]). Variation in 30-day mortality was significant in symptomatic patients (asymptomatic: CEA, 0%-1.3% [P = .2], CAS, 0%-2.4% [P = .2]; symptomatic: CEA, 0%-1.8% [P < .01], CAS, 0%-4.6% [P = .01]). Rates of in-hospital stroke, postoperative myocardial infarction, prolonged length of stay (>2 days), and use of intravenous blood pressure medications all varied significantly across the regions. After CEA, there was significant variation in the rates of cranial nerve injuries (asymptomatic, 0.9%-4.9% [P < .01]; symptomatic, 1.5%-7.7% [P < .01]), return to the operating room (asymptomatic, 0.9%-3.4% [P < .01]; symptomatic, 0.6%-3.4% [P = .02]), and discharge on antiplatelet and statin (asymptomatic, 75%-87% [P < .01]; symptomatic, 78%-91% [P < .01]). After CAS, significant variation was found in the rates of access site complications (asymptomatic, 2.3%-18.2% [P < .01]; symptomatic, 1.4%-16.9% [P < .01]) and discharge on dual antiplatelet therapy (asymptomatic, 79%-94% [P < .01]; symptomatic, 83%-93% [P < .01]). CONCLUSIONS: Unwarranted regional variation exists in outcomes after carotid artery revascularization across the regions of the VQI. Significant variation was seen in a number of outcomes for which quality metrics currently exist, such as length of stay and discharge medications. In addition, after CAS, several regions failed to meet the AHA guidelines for stroke and death. Given these results, quality improvement projects should be targeted to improve adherence to current guidelines to promote best practices.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shean KE, O'Donnell TFX, Deery SE, et al. Regional variation in patient outcomes in carotid artery disease treatment in the Vascular Quality Initiative. J Vasc Surg. 2018. PMID: 29571620. doi:10.1016/j.jvs.2017.11.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。